Study Complete
Sponsor ID
20090203
A study to evaluate the dosing of AMG 827 for subjects with Inadequately Controlled Asthma
Study Details
The purpose of this study is to determine if AMG 827 is effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores.
Protocol Summary
Primary Outcome Measures
The primary objective is to determine if AMG 827 is effective compared to placebo as mesasured by change in Asthma Control Questionnaire (ACQ) composite scores from baseline to week 12.
Timeframe: 12 weeks
Secondary Outcome Measures
Evaluate the efficacy of AMG 827 as measured by Pre- and post-bronchodilator FEV1 (forced expiratory volume in 1 second)
Timeframe: 12 weeks
Evaluate the efficacy of AMG 827 as measured by am and pm Peak expiratory flow rate (PEFR)
Timeframe: 12 weeks
Evaluate the efficacy of AMG 827 as measured by use of rescue Short Acting β-Agonist (SABA) use
Timeframe: 12 weeks
Evaluate the efficacy of AMG 827 as measured by daily asthma symptoms (aggregate/night and individual)
Timeframe: 12 weeks
Evaluate the efficacy of AMG 827 as measured by Asthma Quality of Life Questionnaire (AQLQ) score
Timeframe: 12 weeks
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Los Angeles, California, United States
Status
Recruiting
Location
Research Site
Huntington Beach, California, United States
Status
Recruiting
Location
Research Site
San Diego, California, United States
Status
Recruiting
Location
Research Site
Stockton, California, United States
Status
Recruiting
Location
Research Site
Encinitas, California, United States
Status
Recruiting
Location
Research Site
Colorado Springs, Colorado, United States
Status
Recruiting
Showing {first} - {last} of {total} Results